Recovery of CMV-Specific CD8+ T Cells and Tregs after Allogeneic Peripheral Blood Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 4, 2011, Pages 550-557

  Pastore, Domenico ^a   Delia, Mario ^a   Mestice, Anna ^a   Perrone, Tommasina ^a   Carluccio, Paola ^a   Gaudio, Francesco ^a   Giordano, Annamaria ^a   Rossi, Antonella Russo ^a   Ricco, Alessandra ^a   Leo, Manuela ^a   Liso, Vincenzo ^a   Specchia, Giorgina ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Allogeneic SCT; CMV specific CD8+ T cells; Tregs

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; TETRAMER; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT VERSUS HOST DISEASE; ADAPTIVE IMMUNITY; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MICROENVIRONMENT; NEUTROPHIL COUNT; REGULATORY T LYMPHOCYTE; SEROLOGY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 79952625071     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.04.011     Document Type: Article

References (33)

1. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges and future strategies. Biol Blood Marrow Transplant 2003, 9:543-588.
2. Zaia J.A., Sissons J.G., Riddel S., et al. Status of cytomegalovirus prevention and treatment in 2000. Hematology (Am Soc Hematol Educ Program) 2000, 339-355.
3. Boeckh M., Leisenring W., Riddel S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
4. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91:78-83.
5. Boeckh M., Garrett Nichols W. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
6. Zaia J., Baden L., Boeckh M.J., et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplantation 2009, 44:471-482.
7. Boeckh M., Ljungman P. How I treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
8. Salzberger B., Bowden R.A., Hackman R.C., Davis C., Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood 1997, 90:2502-2508.
9. Li C.-R., Greenberg P.D., Gilbert M.J., Goodrich J.M., Riddell S.R. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994, 83:1971-1979.
10. Peggs K.S., Verfuerth S., Pizzey A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362:1375-1377.
11. Aubert G., Hassan-Walker A.F., Madrigal J.A., et al. Cytomegalovirus-specific cellular immune responses and viremia in recipient of allogeneic stem cell transplants. J Infect Dis 2001, 184:955-963.
12. Gratama J.W., van Esser J.W., Lamers C.H., et al. Tetramers-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell graft and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001, 98:1358-1364.
13. Lamba R., Carrum G., Myers G.D., et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab. Bone Marrow Transplant 2005, 36:797-802.
14. Cwynarsky K., Ainsworth J., Cobbold M., et al. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplant. Blood 2001, 97:1232-1240.
15. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
16. Dulude G., Roy D.C., Perralut C. The effect of graft-versus-host disease on T cell production and homeostasis. J Exp Med 1999, 189:1329-1342.
17. Wall D.A., Hamberg S.D., Reynolds D.S., Burakoff S.J., Abbas A.K., Ferrara J.L. Immunodeficiency in graft-versus-host disease: mechanism of immune suppression. J Immunol 1988, 140:2970-2976.
18. Nguyen V.H., Shashidhar S., Chang S.D., et al. The impact of regulatory T cells on T-cell immunity following hemtopoietic cell transplantation. Blood 2008, 11:945-953.
19. Zou W. Regulatory T cell, tumor immunity and immunotherapy. Nat Rev Immunol 2006, 6:295-307.
20. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4+CD25+ immune regulatory cells inhibits graft-versus-host-disease lethality. Blood 2002, 99:3493-3499.
21. Trenado A., Charlotte F., Fisson S., et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003, 112:1688-1696.
22. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host-disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
23. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
24. Ohnishi M., Sakurai T., Heike Y., et al. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon- y-enzyme-linked immunospot and human leucocyte antigen tetramer assay with an immunodominant T-cell epitope. Br J Haematol 2005, 131:472-479.
25. Lacey S.F., Diamond D.J., Zaia J.A. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 2004, 10:433-447.
26. Ozdemir E., St John L.S., Gillispie G., et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002, 100:3690-3697.
27. Morita-Hoshi Y., Heike Y., Kawakami M., et al. Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 41:515-521.
28. Hebart H., Daginik S., Stevanovic S., et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 2002, 99:3830-3837.
29. Avetisyan G., Aschan J., Hagglund H., Ringden O., Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007, 40:865-869.
30. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
31. Edinger M., Hoffmann P., Ermann J., et al. CD4+CD25+ regulatory T cells preserve graft versus-tumor activity while inhibiting graft-versus host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
32. Clark F.J., Gregg R., Piper K., et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004, 103:2410-2416.
33. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108:1291-1297.